← All trials
NCT04506983
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2020
- Primary completion
- Aug 10, 2022
- Completion date
- Nov 10, 2022
- First posted
- Aug 10, 2020
- Last posted
- Aug 10, 2020
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tsinghua UniversityLead sponsor
- Tsinghua UniversityStudy director
- Tsinghua UniversityStudy director
- China ImmunotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.